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Purpose: Choroidal melanoma is the most common primary malignant ocular tumor in human adults. Relevant mouse
models of human uveal melanoma still remain to be developed. We have studied the transgenic mouse strain, Tyrp-1-
TAg, to try to gain insight into possible molecular mechanisms common to pigmented ocular neoplasms occurring
spontaneously in the eyes of these mice and human choroidal melanoma. The role of two members of the ETS (E26 avian
leukemia oncogene) family of transcription factors, ETS-1 and ETS-2, has been investigated in many cancers but has not
yet been studied in ocular tumors.
Methods: This is the first study describing the production and distribution of ETS-1 and ETS-2 mRNAs and proteins using
in situ hybridization and immunohistochemistry in murine ocular tissue sections of normal control eyes and tumoral eyes
from mice of the same age. Using semi-quantitative reverse-transcription polymerase chain reaction (RT–PCR) and
western blots experiments, we compared changes in ETS-1 and ETS-2 expression, their protein levels, and the regulation
of some of their target gene expressions at different stages of the ocular tumoral progression in the transgenic mouse
model, Tyrp-1-TAg, with those in normal eyes from control mice of the same age.
Results: In normal control adult mouse eyes, ETS-1 was mostly present in the nuclei of all neuroretinal layers whereas
ETS-2 was mostly localized in the cytosol of the cell bodies of these layers with a smaller amount present in the nuclei.
Both were found in the retinal pigmentary epithelium (RPE). ETS-1 and ETS-2 mRNA and protein levels were much
higher in the ocular tissues of Tyrp-1-TAg mice than in control ocular tissues from wild-type mice. This upregulation was
correlated with tumor progression. We also demonstrated upregulation of ETS-1 and ETS-2 target expressions in Tyrp-1-
TAg mice when comparing with the same target expressions in control mice.
Conclusions: Our findings suggest that ETS-1 and ETS-2 are upregulated in ocular tumors derived from the retinal
epithelium and may be involved in one or several signaling pathways that activate the expression of a set of genes involved
in ocular tumor progression such as those encoding ICAM-1 (intercellular adhesion molecule-1), PAI-1 (Plasminogen
activator inhibitor-1), MCP-1 (monocyte chemoattractant protein-1) and p16 (Cyclin dependent kinase inhibitor 2A).
Simian  virus  40  (SV40)  large  T  antigen  (T  Ag)  is  a
multifunctional, oncoviral protein involved in numerous viral
and  cellular  processes  including  viral  replication,
transcriptional  activation  and  repression,  blockade  of
differentiation, and cell transformation [1]. The ability of T
Ag  to  transform  cells  depends  on  complex  interactions
between  the  viral  oncoprotein  and  various  intracellular
proteins  involved  in  cell  control  [2]  and  transcription
regulation such as p53, [3] pRb, and the Rb-related proteins,
p107 and p130 [4], and CBP/p300 [5]. The directed expression
of SV40 T antigen has led to the development of several
important  transgenic  models  with  spontaneous  epithelial
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tumor formation. However, one must keep in mind that SV40
large T antigen targets multiple cellular pathways to elicit
cellular  transformation  [6,7].  Unlike  cancer  arising  in  the
human population, tumors in genetically engineered mouse
models arise in mice with well defined genetic backgrounds
where  genetic  variability  can  be  minimized.  This  offers
significant advantages for studying tumor pathogenesis and
molecular mechanisms of oncogenesis caused by a single
initiating oncogenic event introduced through the mouse germ
line.
Choroidal  melanoma  is  the  most  common  primary
malignant ocular tumor in human adults. Relevant mouse
models of human uveal melanoma still need to be developed.
The  majority  of  transgenic  lines  produced  have  been
generated using the large T SV40 oncogene and either the
tyrosinase  promoter  or  the  tyrosinase-related  promoter-1
promoter [8,9]. Careful analysis suggests that the tumors in
these models begin in the neonatal period as a peripapillary
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1912multilayered proliferation of retinal pigment epithelial cells.
The early tumor cells are characterized by a spindle shape,
abundant cytoplasm, round nuclei with uniform staining, and
fine granules of melanin pigment [9]. Retinal, choroidal, and
optic nerve invasion occurs in 6-10 weeks. By the end of this
process,  the  cells  have  an  appearance  similar  to  human
choroidal  melanoma  cells  including  increased  basophilia,
nuclear and cytoplasmic polymorphism, prominent nucleoli,
abundant  mitosis  with  tendency  to  metastasize,  and
expression  of  S100  calcium  binding  protein  and  Human
Melanoma  Black  (HMB-45)  antigens.  Tumor  growth
continues  with  age  and  with  retinal  detachment  and
extrascleral extension in most murine models [9]. In some
instances,  the  primary  tumors  seem  to  originate  from  the
retinal pigmentary epithelium (RPE), and in other instances,
they seem to originate from the RPE-choroid interface. It has
also been observed in some instances that choroidal tumor
formation occurs in the presence of normal RPE. Considering
the neuroepithelial origin of RPE and the neural crest origin
of choroidal melanocytes, this may be a non-trivial issue when
studying the molecular mechanisms of tumorigenesis. The
most  likely  explanation  for  the  differences  in  transgenic
expression is that the RPE is more permissive and/or sensitive
to the large T antigen expression than the relatively less active
uveal melanocytes.
We  studied  transgenic  mice  developing  exclusively
spontaneous  malignant  ocular  neoplasms  without  any
associated cutaneous melanoma. The transgenic mice that we
decided  to  investigate  (Tyrp1-TAg)  resulted  from  the
integration of multiple copies into the Y chromosome of an
insert with the expression of SV40 large T antigen under the
control of the tyrosine-related protein-1 promoter (Tyrp1).
This model has been previously described as a model of RPE-
derived tumors metastasizing to the brain, inguinal lymph
nodes, and spleen [10]. Expression of the SV40 T antigen
began at E10.5 and the first abnormalities in the RPE were
observed at E15.5. Rapid progression was observed, leading
to the development of a single malignant melanocytic tumor
in each eye of the transgenic mice and invasion of the choroid.
At the age of about two months, the tumor filled the entire eye,
and  cataracts  were  present  in  the  anterior  chamber.  The
expression of the SV40 T antigen seemed to be confined to
RPE cells. However, several previous studies have shown that
early  oncogenic  sequences  of  SV40  under  transcriptional
control  of  the  tyrosinase  promoter  genetically  predispose
normal melanocytes to their transformation into malignant
melanocytes  [8,11-13].  In  contrast  to  normal  endogenous
Tyrp1 mRNA levels, transgenic expression levels in neural
crest-derived  melanocytes  is  low  or  below  the  detection
sensitivity threshold. This suggests the absence of important
cis-acting  regulatory  elements  favoring  significant
transcription of the large T antigen coding sequence located
within the construct used for producing the transgenic mice
that we investigated, Tyrp1-Tag. Indeed, the promoter of the
tyrosinase-related  family  gene,  Tyrp1,  drives  detectable
transgene expression only in the RPE, even though the gene
is also expressed in melanocytes as observed in Tyrp1 mutant
mice [14]. Although the Tyrp1-TAg transgenic mouse model
of pigmented ocular neoplasm cannot be strictly considered
as a choroidal melanoma, it has many features found in human
choroidal melanoma.
The ETS (E26 avian leukemia oncogene) family is a
diverse  group  of  transcription  factors  involved  in  signal
transduction,  cell  cycle  progression,  differentiation,
angiogenesis,  and  invasiveness  [15].  ETS  proteins  are
mitogen-activated  protein  kinase  (MAPK)–dependent
transcription factors. They contain a conserved winged helix-
turn-helix DNA-binding domain and regulate gene expression
by  binding  to  ETS-binding  sequences  in  the  promoter/
enhancer  regions  of  their  target  genes.  These  domains
specifically recognize the 5′-GGAA/T-3′ sequence [16]. More
than 27 ETS proteins have been identified in humans [17]. The
role of ETS-1 and ETS-2 has been studied for many cancers.
The  Ras/Raf/MERK/Erk  pathway  is  one  of  several
downstream signaling cascades activated by the G protein-
coupled Ras proteins. Once activated, an Erk kinase at the
bottom of this cascade phosphorylates cytoplasmic substrates
and may be translocated to the nucleus. In the nucleus, it
phosphorylates transcription factors, some of which initiate
the immediate and delayed early gene responses. Erk also
phosphorylates several transcription factors including ETS,
Elk-1,  and  SAP-1.  In  some  cancers,  signaling  pathways
downstream  from  Raf  may  be  strongly  activated  in  the
absence of direct Ras involvement. Thus, in 60%-70% of
melanomas, a closely related functional analog of Raf, B-Raf,
is found in a mutated constitutively activated form. It remains
unclear why proliferation in these melanomas is driven by
mutant B-Raf rather than mutant Ras. Highly conserved ETS
protein  orthologs  are  present  in  several  species  including
mouse, chicken, nematode, Xenopus, and Drosophila. We
focused our study on two ETS genes, Ets-1 and Ets-2. These
genes seem to be derived from duplication of an ancestral gene
that also gave rise to the Drosophila gene, pointed (Pnt2)
[18,19].  Pnt2  is  involved  in  the  differentiation  of
photoreceptor R7. Based on this known role of ETS-1 and
ETS-2 in photoreceptor differentiation and the current lack of
knowledge concerning the role of these transcription factors
in normal murine retina, we decided to study the production
and roles of these two proteins in the normal mouse retina
including RPE and in the Tyrp1-TAg transgenic mouse model
of  pigmented  ocular  neoplasm.  ETS-1  and  ETS-2  are
produced in various tissues [20]. The role of ETS-1 in cancer
has been studied extensively [21]. However, much less is
known  about  the  role  of  this  protein  in  the  normal  and
pathologic central nervous system of which both the RPE and
the neural retina are major components. The production of this
protein may play a major role in the pathogenesis and may be
predictive of aggressive cutaneous melanoma as it is present
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1913in melanocytic lesions [22]. It is also produced in various solid
tumors  including  epithelial  tumors,  sarcomas,  and
astrocytomas [21]. High ETS-1 levels in breast, ovary, and
cervical  carcinomas  are  associated  with  a  poor  prognosis
[23,24].  ETS-1  is  a  prognostic  marker  of  breast  cancer,
independent of other tumor markers such as nodal status,
tumor  size,  histological  grade,  or  estrogen  receptor  status
[25].  The  presence  of  ETS-1  is  associated  with  a  high
incidence of lymph node metastasis in the lung, colorectal,
and squamous cell carcinoma [26,27]. ETS-1 is also present
in  large  amounts  in  leukemic  T  cells  [28].  The  ETS-1
transcription  factor  is  involved  in  two  other  major
carcinogenic  processes,  metastasis  and  angiogenesis.  The
gene  encoding  this  factor  is  coexpressed  with  the  genes
encoding uPA (urokinase type plasminogen activator) and
MMP-1  (matrix  metalloproteinase-1)  in  various  types  of
tumor [29,30]. ETS-1 is also produced together with MMP-2
and MMP-9 in pancreatic cancer [31]. The importance of
ETS-1 in cancers may be partly accounted for by the role of
this  factor  in  angiogenesis.  Several  members  of  the  ETS
family  have  a  combinatorial  effect  on  vasculature
development [32]. Indeed, oligonucleotides or transdominant
mutant  ETS-1  molecules  with  dominant  negative  effects
inhibit angiogenesis [33,34], consistent with a critical role for
ETS-1 in angiogenesis. However, ETS-1 null mice have no
detectable vascular defects [35-37]. ETS-1 regulates several
downstream  effectors  of  angiotensin  II  including  p21CIP,
plasminogen  activator  inhibitor-1  (PAI-1),  vascular  cell
adhesion  molecule  1  (VCAM-1),  and  monocyte
chemoattractant  protein-1  (MCP-1)  and  plays  a  very
important role in inflammation and vascular remodeling in
response to angiotensine 2 (Ang II) [38] as shown by in vitro
and in vivo experiments. This model makes it possible to
determine whether this is also the case in a mouse model of
eye cancer in which angiogenesis probably plays a major role
in the development of the primary tumor and its local and
distal propagation, leading to the formation of metastases.
ETS-2 has mostly been studied in association with Down
syndrome. ETS-2 transactivates the β APP gene promoter
[39]  and  the  upregulation  of  this  gene  induces  neuronal
apoptosis [40,41]. However, ETS-2 has also been implicated
in  prostate  cancer  [42]  and  together  with  other  factors
including  ETS-1,  SRC-1  (v-src  avian  sarcoma  [Schmidt-
Ruppin  A-2]  viral  oncogene  homolog),  AIB-1  (nuclear
receptor  coactivator  3)  and  NcoR  (nuclear  receptor  co-
repressor) [43,44], breast cancer. ETS-2 and ERM (ets variant
5)  also  significantly  increase  transcription  of  the  gene
encoding intercellular adhesion molecule-1 (ICAM-1) [45],
which has a major role in uveal tumor growth [46]. The roles
of these factors in the eye are unknown.
Here,  we  describe  major  roles  for  these  transcription
factors in a mouse model of ocular cancer. This model has
been  used  as  an  ocular  cancer  mouse  model  to  test  new
potential therapies for human choroidal melanoma [47]. Our
study is the first to demonstrate the production of ETS-1 and
ETS-2  in  normal,  whole  mouse  eyes  during  postnatal
development and adulthood. Both ETS-1 and ETS-2 were
detected in various ocular cell types. We also investigated the
levels and roles of these factors in the mouse Tyrp-1-TAg
transgenic  model  of  ocular  cancer.  Levels  of  mRNA  and
protein  for  these  two  transcription  factors  were  higher  in
abnormal mouse eyes during the development of tumors than
in normal control eyes of the same age. We also demonstrated
an  upregulation  of  various  known  targets  of  these
transcription factors that is part of a developmental pathway
potentially involved in ocular cancer progression.
METHODS
Animals: All animals were handled in compliance with the
Association  for  Research  in  Vision  and  Ophthalmology
(ARVO) statement for use of animals in ophthalmic and vision
research. Animals were kept at 21 °C with a 12 h light (100 lx)/
12 h dark cycle and with free access to food. We studied
normal CB6 mice (WT) and transgenic CB6 Tyrp-1-TAg
mice [10] between the ages of P15 and three months.
Riboprobe synthesis: The ETS-1 and ETS-2 riboprobes were
451 and 503 bp long, respectively, and were synthesized using
a polymerase chain reaction (PCR)-based in situ hybridization
technique  as  previously  described  [48,49].  PCR  was
performed  with  ETS-1  or  ETS-2  gene-specific  primers,
incorporating a binding site for T7 RNA polymerase. Purified
PCR products were then used for transcription reactions with
T7 forward and reverse primers.
In  situ  hybridization:  ETS-1  and  ETS-2  riboprobes  were
labeled with a 10X digoxigenine (DIG) RNA labeling kit
(Promega, Charbonnieres, France). In situ hybridization was
performed on deparaffinized, rehydrated 5 µm eye sections
from CB6 control animals. Tissue sections were incubated
overnight  at  65  °C  with  the  probes  and  washed  with  1X
Stringent  Wash  Concentrate  (Dako,  Glostrup,  Denmark)
according to the manufacturer’s instructions. Tissue sections
were then incubated for 1 h at room temperature with anti-
DIG–AP (alkaline phosphatase-conjugated antibody against
DIG) and rinsed in PBS. Tissue sections were incubated with
the AP substrate, nitro-blue tetrazolium/5-bromo-4-chloro-3-
indolyl-phosphate  (NBT/BCIP),  for  30  min  in  the  dark.
Hybridized  tissue  sections  were  examined  under  a  light
microscope (LEICA, Solms, Germany). Similar amounts of
probe (sense or antisense) were applied to each slide, and all
slides were treated similarly in the same experiment to ensure
that they could be compared. Experiments were performed in
triplicate,  and  results  were  analyzed  by  two  independent
investigators.
Peroxidase/DAB  immunohistochemistry:  Deparaffinized,
rehydrated 5 µm eye and brain sections from CB6 control mice
were  incubated  overnight  at  4  °C  with  antibodies  against
ETS-1 (1:500; sc-350, Santa Cruz Biotechnology, Santa Cruz,
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1914CA) or ETS-2 (1:500; sc-351, Santa Cruz Biotechnology)
diluted  in  Dako  antibody  diluent.  Bound  antibodies  were
detected with the ChemMate peroxidase/DAB rabbit/mouse
detection  kit  (Dako)  according  to  the  manufacturer's
instructions.
Immunohistofluorescence: Deparaffinized, rehydrated 5 µm
eye sections were incubated overnight at 4 °C with a 1/500
dilution  of  antibody  against  ETS-1  (sc-350;  Santa  Cruz
Biotechnology) or ETS-2 (sc-351; Santa Cruz Biotechnology)
in blocking solution. Sections were washed in 1X PBS and
incubated with a 1/200 dilution of goat anti-rabbit Alexa Fluor
488 antibody in a dark chamber. Tissue sections were then
washed with PBS in the dark and mounted in DakoCytomation
fluorescence mounting medium. Tissue sections were stored
at 4 °C until microscopic analysis.
Reverse-transcription  polymerase  chain  reaction:  CB6
Tyrp-1 (n=5) and control mouse (n=5) eyes were removed at
postnatal (P) stages P15, P20, P25, and P30 and at three
months (adult). Total RNA was extracted with an extraction
reagent (TRIzol; Invitrogen-Gibco, Paisley, UK) according to
the  manufacturer’s  instructions.  Total  RNA  (1  µg)  was
reverse-transcribed with reverse transcriptase (SuperScript II;
Invitrogen-Gibco)  and  oligo-dT  primer  according  to  the
manufacturer’s instructions. For semi-quantitative PCR, the
number  of  cycles,  amount  of  cDNA,  and  annealing
temperature were optimized (data not shown). The cyclophilin
gene was amplified as an internal control. PCR was then
conducted  in  10  µl  of  reaction  mixture  containing  0.5  µl
cDNA, 1 µl 10X PCR buffer (Promega, Madison, WI), 1 µg
of each specific (5’-3’) and (3’-5’) primers corresponding to
each cDNA of interest amplified by PCR, 0.5 µg of each
cyclophilin primer (5’-3’ and 3’-5’), 0.2 mM dNTP, 1.5 mM
MgCl2,  and  0.1  U  Taq  DNA  polymerase.  An  initial
denaturation step at 94 °C for 2 min was followed by 29 cycles
of heating for 1 min at 94 °C, 1 min at 55 °C, and 1 min at
72 °C.
The ETS-2 primers (5′-CAT CCT CTG GGA ACA TCT
AG-3′  and  5′-TAC  CCG  CTG  TAC  ATC  CAG  TA-3′)
amplified a 451 bp product. The ETS-1 primers (5′-AAA GAG
TGC TTC CTC GAG CT-3′ and 5′-AGG CTG TTG AAG
GAT  GAC  TG-3′)  amplified  a  503  bp  product.  The
cyclophilin primers (5′-TGG TCA ACC CCA CCG TGT TCT
TCG-3′ and 5′-TCC AGC ATT TGC CAT GGA CAA GA-3′)
amplified a 311 bp product. We also used GAPDH as a second
control gene (data not shown).
Signal  was  quantified  with  Scion  image  software
(Frederick,  MD).  The  experiments  were  performed  three
times. We also tested different groups of primers for each
gene.
Statistical analysis: All results are expressed as the mean±SD.
The  results  were  compared  using  analysis  of  variance
(ANOVA) and Student’s t-test. A p<0.001 was considered
statistically significant.
Western blotting: Total proteins were extracted from CB6
control (n=5) and CB6 Tyrp-1 mouse (n=5) eyes at P15, P20,
P25, P30, and three months of age using an extraction reagent
(TRIzol; Invitrogen-Gibco) according to the manufacturer’s
instructions. Proteins (50 μg; Bradford protein assay) were
separated  by  electrophoresis  (SDS–PAGE  in  a  10%
polyacrylamide gel). Separated proteins were transferred onto
a  nitrocellulose  membrane  (Trans-Blot  Transfer  Medium;
Bio-Rad,  Hercules,  CA),  which  was  then  blocked  by
incubation for 1 h with 5% nonfat milk. Membranes were then
incubated overnight with rabbit anti-ETS-1 antibody (sc-350;
Santa  Cruz  Biotechnology),  anti-ETS-2  antibody  (sc-351;
Santa Cruz Biotechnology), or a goat anti-β-actin antibody
(Santa  Cruz  Biotechnology).  They  were  then  washed  and
incubated for 1 h with a horseradish peroxidase-linked anti-
rabbit or anti-goat secondary antibody (Santa Cruz). Proteins
were  detected  by  enhanced  chemiluminescence  (ECL;
PerkinElmer Life and Analytical Sciences Inc, Courtaboeuf,
France). The experiments were performed three times.
RESULTS
ETS mRNA and protein localization in adult mouse eyes: The
genes, Ets-1 and Ets-2, seem to be derived from duplication
of an ancestral gene that also gave rise to the Drosophila gene,
pointed (Pnt2). This gene is involved in the differentiation of
the photoreceptor, R7, suggesting that ETS-1 and ETS-2 may
be involved in the development and/or biological functions of
the neural retina. We used in situ hybridization to study the
distribution of ETS-1 and ETS-2 mRNA in paraffin-embedded
sections of adult mouse eye tissue. We detected mRNA for
both ETS-1 and ETS-2 in the neuroretina (Figure 1A,E). We
found mRNA for these factors in the ganglion cell layer (GC),
inner nuclear layer (INL), outer nuclear layer (ONL), and
photoreceptor  inner  segments  (PIS)  but  not  in  the
photoreceptor  outer  segments.  Both  transcripts  were  also
present in the adult retinal pigment epithelium (RPE; Figure
1A,E)  and  uveal  melanocytes.  ETS-1  mRNA  was  not
produced in detectable amounts in the outer plexiform layer
whereas ETS-2 mRNA was clearly produced in significant
amounts in this layer, which consists primarily of fibers and
synapses. This observation was validated in several sets of
repeated experiments.
We  also  performed  immunohistofluorescence  and
immunohistochemistry  analyses  to  determine  the  cellular
distribution of ETS-1 and ETS-2 immunoreactivity in the
adult mouse retina (Figure 1B,F and Figure 2). The negative
controls of ETS-1 (Figure 1C) and ETS-2 (Figure 1G) in situ
hybridization and the negative controls of ETS-1 (Figure 1D)
and  ETS-2  (Figure  1H)  immunohistofluorescence  are
presented in Figure 1. The retinal pattern of immunoreactivity
for ETS-1 matched the retinal distribution of ETS-1 transcripts
(Figure  1B).  We  detected  ETS-1  immunoreactivity  in  the
nerve fiber layer (NFL), the ganglion cell layer (GCL), the
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1915INL (with apparent stronger labeling of the bipolar neuron cell
bodies  on  either  side  of  the  INL  and  significant  labeling
probably of the cell bodies of amacrine cells). Horizontal cell
bodies were detected at the interface of the ONL and INL on
the basis of morphological criteria. However, double-labeling
experiments  are  required  to  confirm  unambiguously  the
nature of the cell bodies immunolabeled for ETS-1 in the INL
and in the region close to the ONL. No significant ETS-1
immunostaining  was  observed  in  the  IPL  whereas  ETS-2
immunostaining was strong in this cell layer in adult mice.
ETS-1 immunoreactivity in the OPL was detectable but much
weaker than ETS-2 immunoreactivity in the same layer, which
was very strong (Figure 1F). ETS-1 immunolabeling in the
ONL was weaker than that in the INL, but both the nuclei and
cytoplasm of the ONL cells appeared to be stained. The RPE
displayed  strong  levels  of  immunoreactivity  for  ETS-1
(Figure 2A,C), and significant ETS-1 immunostaining was
also detected in uveal melanocytes. ETS-2 immunoreactivity
was  detected  in  the  adult  mouse  retina,  but  its  cellular
distribution differed from that of ETS-1 (Figure 1D). The
ETS-2 antibody used seemed to almost exclusively stain the
cytoplasm surrounding the nuclei of cells in the GCL, ONL,
INL, and RPE cell layer. We also detected distinct ETS-2
immunostaining in the nerve cell layer, GCL, IPL, and PIS
layer (Figure 2B,D,F). We found positive immunolabeling for
ETS-2 in the nucleus and cytoplasm of some cells in the INL,
Figure  1.  Distribution  of  ETS-1  and
ETS-2 mRNAs and proteins in the adult
mouse  eye.  The  ETS-1  and  ETS-2
mRNAs were detected in adult mouse
tissue sections by in situ hybridization
(HIS), and their distributions are shown
(A and E, respectively). The ETS-1 and
ETS-2  proteins  were  detected  by
immunohistofluorescence  (IHC)  in
adult mouse tissue sections. The specific
immunostaining  patterns  obtained  are
also shown (B and F, respectively). The
retinal tissue distributions of ETS-1 (B)
and ETS-2 (F) proteins appeared to be
somewhat  different  whereas  the
distribution  of  the  transcripts
corresponding to these proteins (A and
E) seemed to be similar in adult mouse
retina.  The  ETS-1  (C)and  ETS-2  (G)
mRNAs show the negative control in
adult mouse tissue sections by in situ
hybridization  obtained  with  sense
riboprobes. The ETS-1 (D) and ETS-2
(H)  immunohistofluorescence  shows
the  negative  control  in  adult  mouse
tissue section. The results were obtained
with  the  second  antibody  alone.  The
nucleus was counterstained with DAPI.
The scale bar represents 100 µm. GCL:
ganglion cell layer; IPL: inner plexiform
layer; INL: inner nuclear layer; OPL:
outer  plexiform  layer;  ONL:  outer
nuclear  layer,  RPE:  retinal  pigment
epithelium;  PIS:  photoreceptor  inner
segment.
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1916but most cell bodies of the INL displayed essentially cytosolic
ETS-2 immunostaining mostly at the periphery of the labeled
cells. In some cases, the staining surrounded the nuclei and
appeared  to  be  very  close  to,  if  not  associated  with,  the
cytoplasmic membranes. Examination of eye tissue sections
under  a  fluorescence  microscope  at  low  and  medium
magnification  did  not  reveal  significant  immunoreactivity
signals  for  ETS-2  in  the  ONL.  However,  at  high
magnification, the nuclei of ONL cells resembled ghost nuclei
surrounded  by  the  weakly  labeled  ETS-2-immunoreactive
cytosol. Immunoperoxidase labeling for ETS-2 was positive
in all the cell bodies located in the GCL, INL, ONL, and RPE
cell  layer,  demonstrating  greater  homogeneity.  With  this
technique,  only  the  cytosol  appeared  to  be  significantly
labeled,  although  much  less  strongly  compared  to  ETS-1
immunostaining. Significant ETS-2 immunostaining of the
OPL was clearly visible. The ETS-2 immunoreactivity in the
RPE and uveal melanocytes was significant but much weaker
Figure  2.  Distribution  of  ETS  transcription  factor  proteins  in  mouse  adult  retina,  cornea,  and  ciliary  body  as  determined  by
immunohistofluorescence. Immunohistofluorescence for ETS-1 and ETS-2 is shown (A-D). ETS-1 (A and C) is present in the ganglion cell
layer (GCL) and inner nuclear layer (INL) with intense homogeneous staining in the outer nuclear layer (ONL). It is also detected in the
photoreceptor inner segment (PIS) and retinal pigment epithelium (RPE). ETS-2 (B and D) is also present in significant amounts in the GCL.
Weak  ETS-2  immunoreactivity  is  observed  in  the  INL  and  ONL.  In  these  layers,  at  higher  magnification,  very  few  cell  bodies  are
immunostained. The immunolabeling detected seems to be restricted to the nuclear membranes whereas the nucleoplasm seems to be devoid
of  ETS-2  immunolabeling.  In  contrast  to  what  was  observed  for  the  retinal  distribution  of  ETS-1  immunoreactivity,  strong  ETS-2
immunolabeling is observed in the inner plexiform layer (IPL) and outer plexiform layer (OPL). As observed for ETS-1, the PIS and RPE
display marked ETS-2 immunostaining, although the RPE seems to be less strongly stained for ETS-2 than for ETS-1. ETS-1 (E) and ETS-2
(F) protein distributions are shown in the adult retina with the DAB immunostaining protocol. We observed ETS-1 (G) and ETS-2 (H)
immunolabeling in the adult ciliary body. In the ciliary body, ETS-1 and ETS-2 proteins are detected in the nonpigmented ciliary epithelial
cells (NPCE). No significant labeling is observed in the pigmented ciliary epithelial cells (PCE). ETS-1 immunolocalisation was detected in
the adult cornea at low (I) and high (K) magnification. ETS-2 immunolocalisation was detected in the adult cornea at low (J) and high (L)
magnification. In the cornea, ETS-1 and ETS-2 immunoreactivities are observed in the epithelium (CEp), the stroma (CS), the stromal
keratocytes (ke, arrows), and the endothelium (CEn).
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1917than  ETS-1  immunoreactivity  in  the  same  cell  types.  We
cannot exclude the possibility that Müller cells were also
immunostained for ETS-2 whereas this seems less likely for
ETS-1. No difference in the respective patterns of ETS-1 and
ETS-2 immunostaining was detected during postnatal ocular
development between P15 and adulthood. The most striking
differences between the retinal immunostaining patterns for
ETS-1 and ETS-2 were the stronger immunolabeling of the
IPL and OPL for ETS-2 than for ETS-1 and the much lower
immunoreactivity of the ONL for ETS-2 than for ETS-1.
We also detected immunoreactivity for ETS-1 and ETS-2
in other adult mouse eye structures (Figure 2) such as the
ciliary bodies, corneal epithelium, keratocytes, and corneal
endothelial cells. In the mouse adult retina, ETS-1 is mostly
present in the nuclei while ETS-2 is mostly present in the
cytosol with smaller amounts present in the nuclei. ETS-2 was
present in large amounts in dendritic, synaptic, and axonal
retinal areas. The possibility of a structural role for ETS-2 in
addition to its role as a transcription factor cannot be ruled out
for retinal neurons. These findings suggest that ETS-1 and
ETS-2 have overlapping but distinct roles in the biological
functions of the eye.
ETS-1 and ETS-2 are upregulated in a murine model of ocular
cancer: We investigated the roles of ETS-1 and ETS-2 in the
development of pigment neoplasms using semi-quantitative
RT–PCR to compare mRNA levels for ETS-1 and ETS-2 in
normal  (WT)  and  tumoral  mouse  model  (TYRP-1-TAg)
whole eyes. Cytophilin was used as an internal standard for
relative quantification of ETS-1 and ETS-2 mRNA levels. We
determined ETS-1 and ETS-2 mRNA levels at P15, P20, P25,
Figure 3. Overproduction of ETS-1 and
ETS-2 mRNAs and proteins in a mouse
model  of  ocular  neoplasm  (Tyrp-1),
with  respect  to  control  mice  (WT)
between P15 and three months. mRNA
levels  were  determined  by  semi-
quantitative  RT–PCR.  The  values
shown  correspond  to  the  levels  of
overproduction  of  ETS-1  and  ETS-2
with respect to levels in normal control
mice at the same age. The graphs (A and
C) show the intensity level of each PCR
band, corresponding to ETS-1 (A) and
ETS-2  (C)  as  measured  by
densitometric analysis. The cyclophilin
is used as an internal standard control.
The  PCR  bands  for  ETS-1  (B)  and
ETS-2  (D)  are  shown.  The  relative
levels  are  calculated  as  the  ratio  of
intensities  of  each  ETS  band  to  the
cyclophilin  band  for  each  lane.  Error
bars  indicate  SEM.  Proteins  were
detected by western blotting (E and F).
Levels  were  quantified  using  Scion
image and normalized using β-actin as
an internal standard (G and H).
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1918P30, and three months of age (Figure 3A,C). The ETS-1/
cyclophilin  mRNA  ratio  in  whole  eyes  almost  doubled
between P25 and three months in TYRP-1-TAg mice but not
in  WT  mice  (Figure  3A).  ETS-2  mRNA  levels  were
significantly higher in the TYRP-1-TAg model than in wild-
type mice. At P25, ETS-2 mRNA levels were more than four
times higher in TYRP-1-TAg than in the wild-type. ETS-2
mRNA levels were slightly lower in TYRP-1-TAg than in WT
mouse eyes at P30 and at three months (Figure 3C).
We investigated the consequences of this upregulation of
ETS-1  and  ETS-2  mRNA  levels  by  western  blotting  to
compare protein levels. We studied ETS-1 and ETS-2 protein
levels at the same time points in Tyrp1-TAg and WT mice
(Figure  3E-H).  ETS-1  and  ETS-2  protein  levels  were
significantly higher in Tyrp1-TAg than in wild-type mice for
all time points between P25 and three months. ETS-1 protein
was first detected in WT eyes at P25 by western blotting. The
exposure time allowing the readily detection of ETS-1 and
ETS-2 by western blotting in the retina of wild-type CB6 mice
gave highly saturated signals for ETS-1 protein extracted from
eyes affected by ocular tumor. However, the levels of ETS-2
protein in eyes with ocular tumor could still be quantified and
interpreted using this exposure time. The ETS-1 signal was
not detected on western blots of normal eyes using shorter
exposure times but was readily detected and quantified on
western blots of ocular tumors from transgenic mice. These
results show a marked increase in protein levels for ETS-1 and
ETS-2 after P25 in transgenic mice compared to the control
mice.
Our findings suggest that the genes encoding ETS-1 and/
or ETS-2 may play a role in the emergence and/or progression
of ocular tumor.
Expression of ETS-1 and ETS-2 in the mass of tumor cells:
We previously observed ETS-1 and ETS-2 overproduction.
However,  the  results  obtained  did  not  determine  whether
ETS-1 or ETS-2 was increased exclusively in the retina and/
or RPE per se and in the ocular tumor only or throughout the
whole  eye.  We  addressed  this  issue  using
immunohistofluorescence to detect these two proteins in the
murine ocular tumor (Figure 4). At P15 and P20, the amounts
and distribution of these proteins were similar between Tyrp-1
TAg and wild-type mice.
We observed specific cellular immunostaining for ETS-1
in the retinal site surrounding the optic nerve at the point of
tumor development at P25 (Figure 4A). The neuroretina was
completely disorganized at the posterior pole of transgenic
mice (Figure 4B) with a mass of cells producing ETS-1. This
mass  of  tumor  cells  (MTC)  forms  a  “collar  button”  or
“mushroom”-like structure, which is highly characteristic of
choroidal melanoma. At three months, this disorganization
was more extensive, spreading from the posterior pole to the
anterior.  We  observed  a  structure  corresponding  to  a
thickening of the pigmentary epithelium producing ETS-1
Figure 4. ETS-1 and ETS-2 distribution in the tumor. We detected ETS-1 protein in the tumor by immunohistofluorescence on 5 µm paraffin-
embedded sections of whole mouse eyes. Distributions of ETS-1 in the posterior pole of Tyrp-1 transgenic mouse eye tissue sections (A) and
in tissue sections from control mice (B) are shown at P25; ETS-1 is significantly expressed in the mass of tumor cells. At three months, the
melanoma tumor reaches the cornea of Tyrp-1 transgenic mice eyes (C) whereas in control mice, only lens fibers can be observed (D). ETS-1
levels are expressed within the mass of tumor cells (MTC). We detected ETS-2 protein by immunofluorescence on 5 µm paraffin embedded
tissue sections. Distributions of ETS-2 protein at P25 in the posterior pole of Tyrp-1 (E) and control mice (F) are also shown; ETS-2 is
significantly expressed in the mass of tumor cells. Distribution of ETS-2 protein at three months in Tyrp-1 (G) and control mice (H). ETS-2
is present within all cells contained within the mass of tumor cells (MTC). The nucleus was counterstained with DAPI. The scale bar represents
100 µm.
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1919(Figure 4C) both in malignant RPE cells and in malignant
melanocytes. Like ETS-1, ETS-2 was produced in the MTC
at the posterior pole at P25 at higher levels in the transgenic
mice  than  in  control  (WT)  mice  (Figure  4E,F).  At  three
months, we also observed a thickening of the pigmentary
epithelium, producing ETS-2 protein at higher levels than in
WT mice (Figure 4G,H).
Overexpression of ETS-1 and ETS-2 target genes in ocular
cancer: We previously showed that the transcription factors,
ETS-1 and ETS-2, were both upregulated from P20 to three
months in our ocular cancer model. We therefore assessed
whether this overproduction of ETS-1 was correlated with an
upregulation of some of its known target genes in our model
of ocular cancer. Three genes are known to be regulated by
ETS-1, MCP-1 (monocyte chemoattractant protein-1), which
has growth promoting effects (reviewed in [50]); p16INK4A
cyclin-dependent kinase, which is directly activated by ETS-1
and  involved  in  replicative  senescence;  and  PAI-1
(plasminogen activator inhibitor type-1), which is considered
a major regulator of tumor invasion and metastasis and of
cancer-related angiogenesis [51]. ICAM-1, which is involved
in angiogenesis, is directly controlled by ETS-2 [45].
We performed semi-quantitative RT–PCR assays on total
RNA from the eyes of normal mice (WT) and transgenic mice
(Tyrp-1-TAg). We quantified mRNA levels for these target
genes  using  the  endogenous  cyclophilin  gene  for
normalization. Levels of mRNA were significantly higher for
all these target genes in Tyrp-1-TAg mice than in wild-type
mice from P20 to three months (Figure 5). This result is
consistent with the higher ETS-1/ETS-2 mRNA and protein
levels observed in these mice. Our data suggest that ETS-1
and ETS-2 are involved in one or more signaling pathways
activating the expression of a set of genes involved in ocular
tumor  progression  and  the  probable  acquisition  of  high
metastatic potential by this tumor. These findings demonstrate
the relevance of one or more signaling pathways, that are
downstream ETS-1 and ETS-2, and the relevance of crucial
molecular building blocks of one or more of these pathways,
in the ocular tumor development occurring in the transgenic
mouse model studied.
DISCUSSION
We  describe  here  the  expression  profiles  for  ETS-1  and
ETS-2,  two  members  of  the  ETS  family  of  transcription
factors.  We  first  investigated  the  pattern  of  ETS-1  and
ETS-2 gene expression in mouse eyes. Previous studies have
reported the detection of ETS transcription factors including
PEA3 [52], ELF3 [53] and ESE-1 [54] in rodent and human
retinas.  In  Drosophila, Pnt2,  the  ortholog  of  ETS-1  and
ETS-2, is involved in eye development [55-57]. Our study is
the first to demonstrate the presence of ETS-1 and ETS-2 in
the mouse eye and to show that these two transcription factors
have different spatial distributions in the mouse neuroretina.
We detected ETS-1 immunoreactivity in the ganglion cell
layer,  the  inner  and  outer  nuclear  layers,  and  the
photoreceptors  inner  segments.  No  significant  ETS-1
immunoreactivity could be detected in any of the plexiform
layers. We also detected ETS-1 immunostaining in the RPE.
ETS-2 immunoreactivity was detected in the GCL, the INL,
the  PIS,  and  the  RPE,  but  no  significant  ETS-2
immunolabeling could be detected in the ONL. This absence
of ETS-2 immunostaining in the ONL suggests that ETS-2 is
not  directly  involved  in  specific  photoreceptor  functions.
Although no ETS-2 immunostaining could be detected in the
ONL, significant ETS-2 immunoreactivity could be observed
in  the  OPL.  These  findings  suggest  that  ETS-2  might  be
involved in synaptic transmission. Further studies are required
to define the role of ETS-1 and ETS-2 in the different retinal
Figure 5. Expression of several known
target  genes  of  ETS-1  and  ETS-2.
ICAM-1,  MCP-1,  PAI-1,  and  p16
mRNA levels were evaluated by semi-
quantitative  RT–PCR  and  normalized
using cyclophilin mRNA as a control.
These  mRNA  levels  were  compared
with those in control mice of the same
age. In A, we observed that ICAM-1 is
upregulated in Tyrp-1 model from p20
to  3  months.  In  B,  we  observed  that
MCP-1 is upregulated in Tyrp-1 model
from p25 to 3 months. In C, we observed
that  PAI-1  is  upregulated  in  Tyrp-1
model from p20 to 3 months. In D, we
observed  that  p16  is  upregulated  in
Tyrp-1 model from p25 to 3 months.
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1920layers. A major finding of our study is the striking difference
observed  between  the  cellular  immunostaining  pattern
observed  for  ETS-1  and  that  observed  for  ETS-2.  While
ETS-1 appeared to be localized mostly in retinal cell nuclei,
ETS-2 seemed to be mostly in the cytosol of retinal cells.
Electron  microscopy  and  live  imaging  experiments  are
required to unambiguously confirm these observations. Our
observations in the retina are consistent with those previously
reported for other parts of the central nervous system (CNS;
data not shown). The differences in tissue and intracellular
ETS-1 and ETS-2 retinal immunostaining patterns suggest
that  ETS-1  and  ETS-2  might  have  different  biological
functions in the adult retina [58]. This contrasts with previous
general  studies  of  the  distribution  of  ETS-1  and  ETS-2.
Indeed, the chicken ETS protein, which contains both the
ETS-1 and ETS-2 domains, is uniformly distributed between
the  cytoplasm  and  nucleus  whereas  in  human  and  other
mammalian  tissues  producing  these  transcription  factors,
ETS-1  localization  is  generally  cytoplasmic  and  ETS-2
localization  is  nuclear.  Differences  in  immunostaining
patterns for these two proteins in neural tissues are consistent
with the notion of different biological functions for ETS-1 and
ETS-2 in the CNS [59].
We then investigated ETS-1 and ETS-2 gene expressions
in a mouse model of pigmented ocular neoplasm. We showed
that ETS-1 and ETS-2 mRNA and protein levels were higher
in these mice than in wild-type mice. This is consistent with
previous studies [17,60,61] that demonstrated the fact both
ETS-1  and  ETS-2  may  play  important  roles  in  the
development  of  ocular  cancer.  We  also  investigated  the
possible role of another member of the ETS family in the
development  of  this  tumor.  GA  BINDING  PROTEIN
(GABP) is an ETS transcription factor required for normal cell
cycle progression [62]. We used semi-quantitative RT–PCR
to assess differences in GABP levels between Tyrp-1-TAg
mice  and  controls.  No  significant  difference  was  found
between transgenic and control mice for GAPB mRNA levels
or in the mRNA levels of GABP target genes, Tymps,Pol-α,
and Skp2 (data not shown). We have so far not found any
evidence suggesting that the increased expression of ETS-1
and ETS-2 observed in these mouse ocular neoplasms resulted
from the inactivation of p53 or Rb. The importance of the large
T antigen interaction with Rb proteins and with p53 in SV40
transformation is well established. However, is this the whole
story  or  do  other  T  antigen  activities  contribute  to  the
tumorigenic phenotype? Indeed, genetic studies suggest that
the inactivation of pRb and p53 may not account for the full
transformation  potential  of  the  T  antigen  [63,64].  Indeed,
several  cellular  T  antigen  binding  proteins  have  been
identified that, based on their known functions, have potential
to contribute to transformation and possibly progression of T
antigen  induced  mouse  tumors  [6].  The  involvement  of
chromatin  and  histone  deacetylation  in  SV40  T  antigen
transcription regulation has been recently demonstrated [65].
Its consequences on ETS-1 and ETS-2 gene expression remain
to be investigated. During malignant transformation, cancer
cells  acquire  genetic  mutations  that  override  the  normal
mechanisms controlling cellular proliferation. Importantly,
malignant progression has been shown to be triggered and/or
accelerated by epigenetic mutations caused by alterations of
DNA  Methyltransferase-1  (DNMT)  [66-69],  histone
acetyltransferase  (HAT),  Histone  deacetylases  (HDACs)
genes,  and  other  mutator  or  modifier  genes.  Histone  tail
modifications  along  with  DNA  methylation  are  the  most
studied epigenetic events related to cancer progression [70].
Another area, which still remains to a large extent a terra
incognita, is related to the transcription factors controlling
ETS-1  and  ETS-2  expression,  although  several  ETS
transcription  factors  have  been  shown  to  be  downstream
effectors  of  the  Ras/Raf/MERK/Erk  pathway.  Our  study
demonstrates that ETS-1 and ETS-2 play a specific role in the
development of T antigen induced RPE tumors.
Penna et al. [10] previously developed a transgenic mouse
model  in  which  the  SV40  T  antigen  induces  RPE  tumor
formation. This transgenic mouse model recapitulates many
features of human choroidal melanoma. Indeed, the tumoral
cells in this model develop an appearance similar to human
choroidal  melanoma  cells  including  increased  basophilia,
nuclear and cytoplasmic polymorphism, prominent nucleoli,
abundant  mitosis  with  a  tendency  to  metastasize,  and
expression  of  S100  and  HMB-45  antigens.  Furthermore,
metastases in this model mostly develop in the liver, the major
location for human choroidal melanoma metastasis. In the
model we investigated, the major site of metastasis is the
brain.  It  should  be  stressed  that  5%  of  human  choroidal
melanomas have metastasis in the brain and not in the liver,
particularly  when  the  human  choroidal  melanoma  occurs
close to the optic disk. Therefore, upregulation of ETS-1 and
ETS-2  could  also  occur  in  choroidal  melanoma.  This
hypothesis has been confirmed by recent findings. Indeed,
microarray gene expression profiling analysis by Harbour and
Onken  [71]  (and  personal  communication)  showed  that
ETS-2 mRNA levels in human choroidal melanoma were four
times higher than those in adult normal melanocytes. These
findings are consistent with those of our study, indicating that
ETS-2  is  indeed  increased  in  the  Tyrp-1  TAg  transgenic
mouse  ocular  pigmented  neoplasms  and  human  choroidal
melanoma.  The  results  obtained  highlight  the  clinical
relevance of this transgenic mouse model for testing new
drugs  to  potentially  overcome  the  high  level  of  chemical
resistance of uveal melanomas [72,73].
Both ETS-1 and ETS-2 were produced at higher levels in
Tyrp-1 TAg mice than in controls. Interestingly, in triplicate
experiments  using  semi-quantitative  PCR  and  western
blotting to compare ocular tumors in Tyrp-1 mice with WT
eyes at the same age, we found that ETS-2 mRNA levels were
higher than ETS-1 mRNA levels, but ETS-1 protein levels
were higher than ETS-2 protein levels. These results may be
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1921accounted  for  by  different  posttranscriptional  regulatory
mechanisms. Primary tumors and their various developmental
stages can now be characterized molecularly by comparative
whole  genome  expression  profiling,  the  use  of  chips  for
mRNA  detection,  and  proteomic  techniques.  MicroRNA
expression in tumors was recently shown to provide valid
specific signatures for each type of tumor [74,75]. The study
of other types of regulatory RNAs might increase the accuracy
of  molecular  characterization  for  each  tumor.  Different
posttranscriptional regulation of ETS-1 and ETS-2 mRNAs by
specific  microRNAs  and/or  RNA-binding  proteins  could
potentially explain our findings. Our observations could also
be explained by epigenetic changes in tumor cells having
differential  effects  on  the  regulation  of  genes  encoding
transcription  factors  and/or  cotranscriptional  regulators  of
ETS-1 and ETS-2. Further experiments are required to test
these hypotheses. For example, the role of Protein Kinase Cα
(PKCα) should be explored because it is implicated in cell
proliferation,  cell  migration,  and  tumor  cell  invasion  in
melanoma [76-79] and increases the stability of the ETS-1
protein [80].
One  role  for  ETS-1  and  ETS-2  in  ocular  cancer  and
choroidal melanoma may be mediated through their increased
transcriptional activity and upregulated expression of their
target  genes  involved  in  angiogenesis  and/or  metastatic
propagation.  ETS-1  and  ETS-2  are  activated  by
phosphorylation  through  Ras/mitogen-activated  protein
kinase signaling [81] but may also be repressed by serine
phosphorylation  [82,83].  Active  ETS  proteins  can
transactivate targeted genes. We studied the expression of
target genes encoding ICAM-1, PAI-1, MCP-1, and p16 to
determine  the  potential  roles  of  ETS-1  and  ETS-2  in  the
development  of  this  tumor.  We  demonstrated  by  semi-
quantitative RT–PCR that ETS-1 and ETS-2 target genes were
upregulated from P20 to the age of three months in these mice,
consistent with our observations for ETS-1 and ETS-2 mRNA
and protein levels. These findings strongly suggest that both
ETS-1 and ETS-2 are upregulated in this mouse model of
ocular tumor with higher levels of transcriptional activity than
in  control  mice.  These  effects  may  be  involved  in  the
pathogenic mechanisms of this disease. Most ETS factors are
oncogenic [17], and the upregulation of ETS gene expression
has been described in many types of human tumors. The levels
of expression of these genes are correlated with invasion and
metastasis and may be useful for predicting tumor progression
in cancer patients. ETS-1 has also been implicated in various
pathways  involved  in  tumor  angiogenesis  through  the
activation of various target genes. It is active in esophageal
squamous cell carcinoma [84], testicular germ cell tumors
[85],  ovarian  cancer  [86,87],  and  gastric  cancer  [88,89].
Vascular remodeling is a key feature of all these cancers. A
large body of data suggests that tumor growth involves normal
and abnormal vascular processes, nourishing tumor cells, and
favoring their multiplication. Therefore, it is hardly surprising
that the growth of human uveal melanomas is associated with
abnormal  vascularization  processes.  An  ability  to  form
vascular loops has recently been identified as an important
prognostic  factor  in  choroidal  melanoma.  Tumors  may
develop an intricate pattern of microcirculation independent
of  angiogenesis.  In  aggressive  primary  and  metastatic
melanomas,  the  tumor  cells  generate  acellular
microcirculatory channels composed of extracellular matrix
and lined externally by tumor cells. The de novo generation
of vascular channels by aggressive and metastatic tumor cells
is  not  strictly  vasculogenic  because  true  vasculogenesis
results  in  the  de  novo  formation  of  endothelial  cell-lined
vessels.  This  “vasculogenic  mimicry”  allows  aggressive
tumor cells to generate non-endothelial cell-lined channels
delimited by the extracellular matrix [90]. These cells produce
vascular  endothelium-cadherin  (VE-cadherin),  express  the
vascular endothelial growth factor (VEGF) receptor, and have
high levels of metalloproteinase activity [91]. The acquisition
of a more classical angiogenic phenotype is also required for
the malignant progression of various solid tumors. Previous
studies have demonstrated that several genes including those
playing an important role in angiogenesis are differentially
expressed  in  human  melanoma  cells  [92].  Further
characterization  of  the  molecular  mechanisms  and
transcription factors involved in the formation of this type of
tumor may lead to the development of alternative methods of
inhibiting or blocking tumor growth and/or interfering with
metastasis.
ETS-1 is a critical regulator of Ang II-mediated vascular
remodeling. Zhan et al. [38] identified several ETS-1 target
gene products (including PAI-1 and MCP-1) involved in this
pathway.  PAI-1  is  a  major  regulator  of  tumor  invasion,
metastasis, and cancer-related angiogenesis [51]. PAI-1 may
interact  with  vitronectin,  which  normally  promotes  cell
adhesion,  spreading,  and  migration  by  interaction  with
integrins [93]. The coupling of PAI-1 to vitronectin prevents
vitronectin-integrin  interaction,  which  downregulates  cell
adhesion.  Similarly,  by  competing  with  plasminogen
activator,  urokinase  (uPA),  the  interaction  of  PAI-1  with
vitronectin inhibits uPA-dependent cell adhesion. PAI-1 is
also  directly  involved  in  tumorigenesis.  Various  cellular
mechanisms  contribute  to  PAI-1-regulated  tumoral  and
choroidal  neovascularization  [94].  PAI-1  protects
neovascularized tissues from excessive proteolysis [95] and
controls in vivo tumor vascularization by interacting with
proteases [96]. However, the upregulation of PAI-1 mRNA
levels may be part of a mechanism to protect the cell from
destruction.  Indeed,  high  levels  of  PAI-1  expression  are
correlated with a poor prognosis in various types of cancer
(gastric, breast, and lung) [97,98].
MCP-1 (or ccl2) is a chemokine that attracts and activates
mononuclear cells. Many studies have shown that MCP-1
promotes tumor growth (for review see [50]). Cancer cells
secrete chemokines to promote tumor growth and progression.
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1922For example, a high level of MCP-1 in breast cancer patients
is associated with a significantly shorter relapse-free survival
period than low levels of MCP-1 [99]. MCP-1 also seems to
be  involved  in  the  recruitment  of  tumor-associated
macrophages  in  several  types  of  cancer  (ovarian,  gastric,
breast, and esophageal) [100-103] and has pro-angiogenic
activity  [104].  The  macrophages  attracted  by  MCP-1  are
potent sources of other angiogenic factors including VEGF.
It therefore remains unclear whether the angiogenic effects of
MCP-1 are direct or mediated by macrophage recruitment and
activation [105]. MCP-1 seems to have a direct effect on
tumors through its effects on angiogenesis [106]. MCP-1-
deficient  mice  were  shown  to  be  protected  in  models  of
endogenous carcinoma development [50].
The p16INK4A cyclin-dependent kinase inhibitor has
been  implicated  in  replicative  senescence,  the  state  of
permanent growth arrest induced by cumulative cell divisions
or  constitutive  Ras-Raf-MEK  signaling  in  somatic  cells.
Ohtani et al. [107] demonstrated a role for ETS-1 and ETS-2
in  the  regulation  of  p16INK4A  production  involving  the
binding to and activation of the p16INK4A gene promoter. We
observed the upregulation of the p16 gene expression in our
model, consistent with the high levels of p16 detected in a
rapidly growing malignant uveal melanoma in a previous case
study [108]. However, other groups have found that p16 gene
expression levels in melanoma cells are lower than or the same
as in normal cells. Similar to our findings, a previous study
demonstrated  an  upregulation  of  p16  in  uveal  melanoma
[109]. They observed upregulation of cyclin D1, cyclin E, and
p16INK4A, together with abnormal pRB and E2F binding.
They concluded that the overproduction of cyclins D1 and E
and Cyclin Dependant Kinases Inhibitor (CDKI) p16 together
with the deregulation of the Rb/E2F pathway may be involved
in the development of human uveal melanoma. Consistent
with this, we observed the upregulation of p16 in a mouse
model of choroidal melanoma in which tumor formation is
induced by the SV-40 T antigen. The gene encoding pRb is a
target of several transforming viral oncoproteins including the
T antigen of SV40 [110]. The upregulation of p16 may also
be due to the upregulation of the microphthalmia-associated
transcription factor (MITF) transcription factor. Like ETS-1,
MITF activates p16 gene expression [111]. MITF has been
described as a highly sensitive immunohistochemical marker
for melanoma diagnosis. MITF gene amplification is involved
in melanoma progression.
We then studied the expression level of the ETS-2 target
gene encoding ICAM-1. ICAM-1 mRNA levels were higher
in this mouse model of choroidal melanoma than in controls.
The  gene  encoding  ICAM-1  is  transactivated  directly  by
ETS-2 [45,112]. ICAM-1 regulates cell–cell and cell–matrix
adhesion, and its role in inflammation has been studied in
detail  [113].  Recent  work  based  on  the  use  of  a  mouse
antibody  against  ICAM-1  has  shown  that  blocking  this
adhesion molecule inhibits the growth of uveal melanoma in
a severe combined immunideficient (SCID) mouse model
[46]. A previous study revealed very high levels of ICAM-1
gene  expression  in  melanomas  [114].  ICAM-1  acts  in
association with neutrophils by inducing polymorphonuclear
(PMN)  cell  degranulation  and  releasing  proteases,  which
break down the endothelial barrier and promote tumor cell
migration during metastasis formation [115]. Our data are
consistent with previous findings. Thus, upregulation of the
production and activity of the ETS-2 transcription factor may
promote cell proliferation and metastasis in this tumor model.
The changes observed in expression levels of ETS target
genes seem modest compared to those of ETS-1 and ETS-2.
This may be due to the involvement of other transcription
factors or transcription regulators possibly acting together at
the promoters of these genes.
ETS-1 and/or ETS-2 could also be involved in epithelial-
mesenchyme transitions (EMT). These transitions include a
variety of intercellular and intracellular changes [116]. EMT
plays an important role in the development of many tissues
during embryogenesis, but similar cell changes occur during
pathological processes such as cancer development. ETS-1 is
produced during EMT [117]. Further experiments are required
to  confirm  the  involvement  of  ETS-1  and  ETS-2  in  this
process.
In conclusion, this study shows that ETS-1 and ETS-2
may  play  a  major  role  in  choroidal  melanoma.  We  have
characterized  the  distribution  of  these  two  transcription
factors in the normal and diseased eye. The upregulation of
these proteins was correlated with upregulation of their target
genes in a mouse model of ocular neoplasm. Thus, ETS-1 and
ETS-2 may be involved in the development of this disease and
are therefore potential targets for choroidal melanoma gene
therapy. The next step could be to explore the consequences
of an upregulation of these ETS transcription factors in normal
human  melanocytes  to  observe  if  these  cells  become
neoplastics.  Our  findings  are  also  consistent  with  those
obtained in the ETS-1-dependent vascular remodeling model
[38], which identifies ETS-1 as a direct target of Ang II in
vascular remodeling mediated by MCP-1 and PAI-1. This
ETS transcription factor, which increases the production of
MCP-1 and PAI-1, both of which are involved in vascular
remodeling, was significantly upregulated in our model. Our
findings  may  have  important  implications  for  the
development  of  new  therapeutic  agents  for  use  in  uveal
melanoma. Indeed, vascular remodeling is known to be a key
factor  in  the  development  of  resistance  to  antiangiogenic
treatment in tumors [118]. Future studies may confirm that
vascular remodeling does indeed occur in this tumor. ETS-1
and angiotensin II receptors would thus be very important
targets for cancer treatment. The study of human choroidal
melanoma tumors should shed light on the role of the genes
encoding  ETS-1  and  ETS-2  in  the  pathogenesis  and
progression of these tumors.
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